Biostock writes in a new article that the study results from Chordate Medical’s PM007 study will be presented at the American Headache Society Scientific Meeting in mid-June and are also available on the organization’s website. The results show that K.O.S. has a significant effect for the preventive treatment of chronic migraine.
“The fact that AHS invites the researchers in the study to present the study results in a lecture format confirms the importance of the study results, which show that K.O.S has a significant clear effect for the preventive treatment of chronic migraine. We see the customary publication of the abstract as very positive because it will contribute to the knowledge about the treatment method spreading faster both in the USA and the rest of the world”, says Anders Weilandt, Chordate CEO, to Biostock.